EGFR and cancer: The first echelon includes C1 (NSCLC), which contains EGFR, EGFR-TKI, EGFR mutation, lung cancer, erlotinib, etc.; and C2 (targeted therapy), which contains renal cell carcinoma, sunitinib, chemotherapy, cancer, tumor, etc. These 2 major subdirections contain the largest number of keywords and the largest sum of frequencies, which are the main subdirections of TKIs research.